Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
NWCJ van de Donk, ML Janmaat, T Mutis… - Immunological …, 2016 - Wiley Online Library
CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues, …
The protein is generally expressed at low levels on various hematological and solid tissues, …
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
NWCJ van de Donk, P Moreau… - Blood, The Journal …, 2016 - ashpublications.org
Immunotherapeutic strategies are emerging as promising therapeutic approaches in
multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical …
multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical …
How I treat plasma cell leukemia
NWCJ van de Donk, HM Lokhorst… - Blood, The Journal …, 2012 - ashpublications.org
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative
disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. …
disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. …
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
P Sonneveld, IGH Schmidt-Wolf… - Journal of clinical …, 2012 - ascopubs.org
Purpose We investigated whether bortezomib during induction and maintenance improves
survival in newly diagnosed multiple myeloma (MM). Patients and Methods In all, 827 eligible …
survival in newly diagnosed multiple myeloma (MM). Patients and Methods In all, 827 eligible …
[HTML][HTML] Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …
reliable tool is needed to stratify patients with MM. We combined the International Staging …
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
M De Weers, YT Tai, MS Van Der Veer… - The Journal of …, 2011 - journals.aai.org
CD38, a type II transmembrane glycoprotein highly expressed in hematological
malignancies including multiple myeloma (MM), represents a promising target for mAb-based …
malignancies including multiple myeloma (MM), represents a promising target for mAb-based …
[HTML][HTML] Targeting CD38 with daratumumab monotherapy in multiple myeloma
HM Lokhorst, T Plesner, JP Laubach… - … England Journal of …, 2015 - Mass Medical Soc
Background Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab,
a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving …
a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving …
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated
mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated …
mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated …
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma
(MM) was previously reported. Here, we present an updated pooled analysis of 148 patients …
(MM) was previously reported. Here, we present an updated pooled analysis of 148 patients …
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
K Neben, HM Lokhorst, A Jauch… - Blood, The Journal …, 2012 - ashpublications.org
In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities
may enable a more rational selection of therapeutic approaches. In the present study, we …
may enable a more rational selection of therapeutic approaches. In the present study, we …
